An overview of meningococcal disease in India: Knowledge gaps and potential solutions

John, T. Jacob; Gupta, Sunil; Chitkara, A. J.; Dutta, A. K.; Borrow, Ray

doi:10.1016/j.vaccine.2013.04.003

Cited by 25 publications

(27 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, although the authors report herein the challenges faced by Latin America and a case definition specific for the region, it should be remembered that the key conclusions and general recommendations can be extrapolated to all other regions of the world. Control efforts, for example, should always focus on educating physicians and regulators on the importance of the disease, its diagnosis, improving meningococcal surveillance and the need for uniform, quality data, and this should be a key aspect for consideration globally (indeed, a separate GMI meeting held in India identified similar key conclusions as noted herein for the Latin American region) [56]. Additionally, other regions should consider developing a uniform meningococcal case definition relevant to their needs to improve surveillance and facilitate data comparisons in that region.…”

Section: Expert Commentarymentioning

confidence: 76%

The current situation of meningococcal disease in Latin America and recommendations for a new case definition from the Global Meningococcal Initiative

Sáfadi

Monteros

López

et al. 2013

Expert Review of Vaccines

View full text Add to dashboard Cite

The Global Meningococcal Initiative (GMI) is an international group of scientists and clinicians with expertise in meningococcal disease (MD). It promotes MD prevention through education and research. Given geographic differences in disease epidemiology, prevention strategies (e.g., vaccination) should be country-specific to ensure local needs are met. However, regional policies/recommendations and standardized disease diagnostic criteria should be implemented to improve surveillance and control strategies, and allow for more robust data comparisons. Consequently, the GMI convened a meeting with Latin American representatives to discuss the burden of MD and vaccination practices/policies, and consider if the global GMI recommendations could be tailored. The group determined that as robust, uniform epidemiologic data are required to make informed health-policy decisions, it would be useful to first summarize the regional situation herein (including disease surveillance, case definitions, epidemiology, vaccination and outbreak control strategies) and then determine a consensus-based meningococcal case definition for use throughout the region.

show abstract

Section: Expert Commentarymentioning

confidence: 76%

The current situation of meningococcal disease in Latin America and recommendations for a new case definition from the Global Meningococcal Initiative

Sáfadi

Monteros

López

et al. 2013

Expert Review of Vaccines

View full text Add to dashboard Cite

show abstract

“…120 , 123 Recent data from the Indian subcontinent are also unavailable, restricted mainly to local outbreaks and epidemics, which occur with regular frequency. 124 In India, however, there have been increasing reports of IMD outbreaks since 2005, mainly affecting adolescents and young adults, and due to MenA. 124 , 125 Whilst current surveillance data are not readily available, N. meningitidis has been reported as a cause of bacterial meningitis in Pakistan.…”

Section: Chinamentioning

confidence: 99%

The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination

Parikh

Campbell

Bettinger

et al. 2020

Journal of Infection

Self Cite

155

176

View full text Add to dashboard Cite

Neisseria meningitidis is a major cause of bacterial meningitis and septicaemia worldwide and is associated with high case fatality rates and serious lifelong complications among survivors. Twelve serogroups are recognised, of which six (A, B, C, W, X and Y) are responsible for nearly all cases of invasive meningococcal disease (IMD). The incidence of IMD and responsible serogroups vary widely both geographically and over time. For the first time, effective vaccines against all these serogroups are available or nearing licensure. Over the past two decades, IMD incidence has been declining across most parts of the world through a combination of successful meningococcal immunisation programmes and secular trends. The introduction of meningococcal C conjugate vaccines in the early 20 0 0s was associated with rapid declines in meningococcal C disease, whilst implementation of a meningococcal A conjugate vaccine across the African meningitis belt led to near-elimination of meningococcal A disease. Consequently, other serogroups have become more important causes of IMD. In particular, the emergence of a hypervirulent meningococcal group W clone has led many countries to shift from monovalent meningococcal C to quadrivalent ACWY conjugate vaccines in their national immunisation programmes. Additionally, the recent licensure of two protein-based, broad-spectrum meningococcal B vaccines finally provides protection against the most common group responsible for childhood IMD across Europe and Australia. This review describes global IMD epidemiology across each continent and trends over time, the serogroups responsible for IMD, the impact of meningococcal immunisation programmes and future needs to eliminate this devastating disease.

show abstract

“…The GMI is an international group of clinicians and scientists with expertise in MD immunology, microbiology, epidemiology, public health, and vaccination. Since its inception, several global and regional meetings have been held and these have resulted in the publication of recommendations, including the GMI Global Recommendations for Meningococcal Disease (Table 2), as well as regional situation reports [11,[30][31][32][33].…”

Section: Introductionmentioning

confidence: 99%

The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection

Borrow

Alarcón

Carlos

et al. 2016

Expert Review of Vaccines

Self Cite

210

229

View full text Add to dashboard Cite

Introduction: The 2015 Global Meningococcal Initiative (GMI) meeting discussed the global importance of meningococcal disease (MD) and its continually changing epidemiology. Areas covered: Although recent vaccination programs have been successful in reducing incidence in many countries (e.g. Neisseria meningitidis serogroup [Men]C in Brazil, MenA in the African meningitis belt), new clones have emerged, causing outbreaks (e.g. MenW in South America, MenC in Nigeria and Niger). The importance of herd protection was highlighted, emphasizing the need for high vaccination uptake among those with the highest carriage rates, as was the need for boosters to maintain individual and herd protection following decline of immune response after primary immunization. Expert commentary: The GMI Global Recommendations for Meningococcal Disease were updated to include a recommendation to enable access to whole-genome sequencing as for surveillance, guidance on strain typing to guide use of subcapsular vaccines, and recognition of the importance of advocacy and awareness campaigns. ARTICLE HISTORY

show abstract

An overview of meningococcal disease in India: Knowledge gaps and potential solutions

Cited by 25 publications

References 32 publications

The current situation of meningococcal disease in Latin America and recommendations for a new case definition from the Global Meningococcal Initiative

The current situation of meningococcal disease in Latin America and recommendations for a new case definition from the Global Meningococcal Initiative

The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination

The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection

Contact Info

Product

Resources

About